Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on August 8, 2022. The report announces financial results for the three months ended June 30, 2022, and provides recent corporate updates. The filing references a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing does not provide specific data to compare current period performance against the prior comparable period. The text only confirms that results for the quarter ended June 30, 2022, were reported.
Guidance, Outlook, and Risks
The filing includes "other recent corporate updates" alongside the financial results but does not detail specific guidance, outlook, management commentary, risks, or unusual items in the provided text. The information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc. (Ticker: SLRX), not Decoy Therapeutics Inc.
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for the quarter ended June 30, 2022.
- Confirm the details of the "recent corporate updates" mentioned in Item 2.02.
- Check the Nasdaq Capital Market listing status for SLRX.